Cannabis
Commented by Armin Schulz on September 20th, 2023 | 08:25 CEST
Canopy Growth, Cantourage Group, Aurora Cannabis - Will the price fireworks come after legalization?
For a long time, there was little reason for cannabis investors to rejoice. However, since Bloomberg reported that the US Department of Health and Human Services has asked the DEA to downgrade cannabis from Schedule 1 to Schedule 3, hopes for legalization are reviving. This downgrade would mean that cannabis would no longer be on par with heroin or other hard drugs. Democrats also want to give businesses in this sector legal access to bank accounts. In Germany, the traffic lights have approved Health Minister Lauterbach's plans to legalize cannabis. We, therefore, look at three companies that are betting on cannabis.
Read
Commented by Stefan Feulner on September 13th, 2023 | 09:55 CEST
Cannabis stocks on a high - Aurora Cannabis, Viva Gold, Canopy Growth
The exorbitant price jumps in the cannabis sector are reminiscent of the golden bull market days between 2015 and 2018. Back then, companies like Canopy Growth saw staggering increases of 5800%, and Aurora Cannabis soared over 6000%. After a years-long dry spell, various companies recently sent strong signs of life with a doubling of the share price within a few days. Additionally, the upward momentum promises to be sustainable as Aurora & Co. slowly move towards profitability.
Read
Commented by André Will-Laudien on September 11th, 2023 | 07:30 CEST
The next steps towards cannabis THC legalization are underway! Canopy, Tilray and BioNTech are taking the lead, and Cantourage Group is experiencing dynamic growth
Cannabis has been decriminalized in some countries but legalized in only a few states. In the US, cannabis is fully legalized in states such as California but outright banned in others such as Texas. While medical use is slowly catching on, the use as an intoxicant and cultivation for personal use remains controversial. Stronger momentum could be sparked by the US Department of Health and Human Services (HHS). The authorities are open to a downgrading of the degree of danger in the categorization of the US Drug Enforcement Administration (DEA). We are talking about two steps from Schedule I to Schedule III, which no longer puts THC on a par with common drugs such as heroin, ecstasy or LSD but classifies them as substances with comparatively little psychological dependence. That would be a revolutionary step. Which stocks can benefit?
Read
Commented by Stefan Feulner on September 6th, 2023 | 07:30 CEST
Cannabis stocks showing signs of life - Aurora Cannabis, Cantourage Group, Canopy Growth
In recent years, the once-hyped cannabis industry was considered a true capital destroyer. Even market leaders like Aurora Cannabis, Tilray, or Canopy Growth saw their stock values plummet by more than 90% at their peak. A letter from the US Department of Health and Human Services has sparked the first signs of a potential revival, which could eventually lead to a sustainable bottoming out in the long run.
Read
Commented by Fabian Lorenz on August 30th, 2023 | 08:30 CEST
Better than Nel & Co.? Megatrend shares Redcare Pharmacy and Cantourage Group recommended as buy
Hydrogen has electrified investors for years. But pure-plays like Plug Power and Nel & Co. are struggling to get their numbers in order and are far from profitable business models. As a result, these shares are not much fun at the moment, and analysts see further downside potential. In such a situation, it is worth taking a look at other megatrend stocks. Redcare Pharmacy (formerly Shop Apotheke) is benefiting from online pharmacy and e-prescription trends. The share has already more than doubled this year. Investors can profit from the cannabis trend with the German Cantourage Group. The Company is growing strongly and the share price has come to rest (before the storm). Both shares are recommended to buy by analysts.
Read
Commented by Juliane Zielonka on August 17th, 2023 | 07:10 CEST
Cantourage, Amazon, Bayer: Young entrants soaring, old players in reorientation
The time has finally come in Germany: the federal government has given the green light for the private use of cannabis. Since 2017, doctors in Germany have been allowed to prescribe cannabis as a therapeutic agent. The growing market in this segment has been recognized by the team at Cantourage, which focuses on the medical production of active ingredients from the hemp plant. The leadership of Bayer could use some relief. Analysts at Berenberg Bank have put the Leverkusen-based company's balance sheet through its paces and discovered a few things that have now downgraded Bayer's stock from Buy to Hold. Amazon's Cloud Business takes another step forward. The Company's in-house AI is moving into the documentation of medical health reports. Find out what it is all about here.
Read
Commented by Stefan Feulner on July 31st, 2023 | 09:50 CEST
BASF, Cantourage Group, Palantir - Now the analysts speak out
Currently, it is high noon for the release of first-half 2023 earnings. Despite all the uncertainties regarding geopolitical and fiscal policy, the majority of companies surprised positively. As a result, the Dow Jones, DAX, Nasdaq and others were able to climb to new highs for the year. Analysts also see further upside potential for many companies, which could accelerate the rally in the coming weeks.
Read
Commented by André Will-Laudien on July 19th, 2023 | 08:00 CEST
Cannabis 3.0 - will profits be made now? Canopy and Tilray under pressure, Cantourage Group positioned superbly
For a few days now, a long-neglected stock market segment has been attracting attention again: the cannabis industry. The North American industry protagonists Canopy and Tilray have recently attracted some stock market turnover again, but skepticism remains high. For those investors who did not exit in time, they had to write off around 95% of their investment in the last 2 years, and experts suspect that the revaluation of the former high-flyers is not yet complete. We take a look at the nebulous scenery of hemp speculation.
Read
Commented by Fabian Lorenz on February 14th, 2023 | 15:46 CET
Biotech stocks on the verge of a breakout? Evotec, BioNTech, Cardiol Therapeutics
Biotech stocks have largely missed out on the rally of recent weeks. But this could change. Some have interesting chart constellations or a positive news flow. Sooner or later, the stock should then also react with a breakout. After the horror year 2022, Evotec received several positive reports within a few days. The share price has also jumped. At BioNTech, investors are looking away from the COVID-19 vaccine and towards the development pipeline. But, analysts disagree. Are 100% share price gains on the cards? Analysts believe that Cardiol Therapeutics' stock has even more potential than that. Its main product against heart inflammation is already in the Phase II pilot study, and the necessary capital for further development is available. All three shares are recommended as a buy by analysts.
Read
Commented by Armin Schulz on February 8th, 2023 | 11:49 CET
BioNTech, Pfizer, Cardiol Therapeutics, Bayer - Biotech stocks facing a revival?
The BIO Deutschland association represents the German biotech industry. According to an announcement on January 18, financing of biotech companies plummeted by 2/3 in 2022. Overall, the sector raised only EUR 920 million in equity. During the Corona pandemic, many biotech stocks did well. Subsequently, profit-taking occurred and rising interest rates put additional pressure on stocks. That could change in 2023. Meanwhile, some companies are valued low, and so these companies appear on the radar of investors from the United States. According to Handelsblatt, Water Street, an investment company focused on pharma and biotech, has already invested EUR 1 billion, mainly in Germany. A total of EUR 6 billion is to be invested.
Read